CA3153921A1 - External preparation for treating epilepsy or autism spectrum disorder - Google Patents
External preparation for treating epilepsy or autism spectrum disorder Download PDFInfo
- Publication number
- CA3153921A1 CA3153921A1 CA3153921A CA3153921A CA3153921A1 CA 3153921 A1 CA3153921 A1 CA 3153921A1 CA 3153921 A CA3153921 A CA 3153921A CA 3153921 A CA3153921 A CA 3153921A CA 3153921 A1 CA3153921 A1 CA 3153921A1
- Authority
- CA
- Canada
- Prior art keywords
- sirolimus
- topical preparation
- gel
- day
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019-189091 | 2019-10-16 | ||
| JP2019189091 | 2019-10-16 | ||
| PCT/JP2020/037986 WO2021075328A1 (ja) | 2019-10-16 | 2020-10-07 | てんかん治療用又は自閉症スペクトラム障害治療用外用剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3153921A1 true CA3153921A1 (en) | 2021-04-22 |
Family
ID=75537453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3153921A Pending CA3153921A1 (en) | 2019-10-16 | 2020-10-07 | External preparation for treating epilepsy or autism spectrum disorder |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240058365A1 (https=) |
| EP (1) | EP4046637A4 (https=) |
| JP (1) | JP7601398B2 (https=) |
| CN (1) | CN114555081A (https=) |
| AU (1) | AU2020365665A1 (https=) |
| CA (1) | CA3153921A1 (https=) |
| WO (1) | WO2021075328A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011526889A (ja) * | 2008-06-30 | 2011-10-20 | アフギン ファーマ,エルエルシー | 局所局部的神経作用療法 |
| DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| CA2825786A1 (en) * | 2011-01-31 | 2012-08-09 | Osaka University | Externally-used drug for treating skin disorder and method for producing same |
| CN104490873A (zh) * | 2014-11-25 | 2015-04-08 | 邹丽萍 | 一种治疗儿童结节性硬化症的药物 |
| JP6541124B2 (ja) * | 2015-03-23 | 2019-07-10 | 国立大学法人大阪大学 | びまん性神経線維腫用の外用薬 |
| US10765665B2 (en) * | 2015-11-24 | 2020-09-08 | Melin Jeffrey | Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases |
-
2020
- 2020-10-07 US US17/766,728 patent/US20240058365A1/en active Pending
- 2020-10-07 CA CA3153921A patent/CA3153921A1/en active Pending
- 2020-10-07 CN CN202080072265.6A patent/CN114555081A/zh active Pending
- 2020-10-07 AU AU2020365665A patent/AU2020365665A1/en not_active Abandoned
- 2020-10-07 JP JP2021552347A patent/JP7601398B2/ja active Active
- 2020-10-07 WO PCT/JP2020/037986 patent/WO2021075328A1/ja not_active Ceased
- 2020-10-07 EP EP20876076.9A patent/EP4046637A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020365665A1 (en) | 2022-04-14 |
| WO2021075328A1 (ja) | 2021-04-22 |
| CN114555081A (zh) | 2022-05-27 |
| JPWO2021075328A1 (https=) | 2021-04-22 |
| JP7601398B2 (ja) | 2024-12-17 |
| EP4046637A4 (en) | 2023-11-01 |
| US20240058365A1 (en) | 2024-02-22 |
| EP4046637A1 (en) | 2022-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101267901B1 (ko) | 프로스타글란딘 e₁을 포함하는 에멀션 조성물 | |
| EP2120860B1 (en) | Pharmaceutical compositions and method for treating inflammation in cattle and other animals | |
| CA2728727C (en) | Pharmaceutical transdermal compositions and method for treating inflammation in cattle | |
| JP2016130224A (ja) | 外用組成物 | |
| KR101817028B1 (ko) | 지속성 케토프로펜 조성물 | |
| KR101894521B1 (ko) | 흉터치료를 위한 국소용 약학적 조성물 | |
| JP6541124B2 (ja) | びまん性神経線維腫用の外用薬 | |
| US20240058365A1 (en) | External Preparation for Treating Epilepsy or Autism Spectrum Disorder | |
| JP2011102260A (ja) | タクロリムス外用剤 | |
| KR101018819B1 (ko) | 티오우레아 유도체를 함유하는 소양성 또는 자극성피부질환의 예방 또는 치료용 외용제 조성물 | |
| HUT74448A (en) | Process for preparing pharmaceutical compns. contg. ibuprofen and flurbiprofen for use as anti-pruritic agents | |
| JP7446711B2 (ja) | 皮膚外用組成物 | |
| HK40065801A (zh) | 用於治疗癫痫或用於治疗自闭症谱系障碍的外用剂 | |
| EP3932487A1 (en) | External preparation for vascular abnormality treatment | |
| JP7514598B2 (ja) | 皮膚外用組成物 | |
| WO2019002367A1 (en) | TOPICAL COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | |
| JP2003534277A (ja) | 生存性改善 | |
| EP3305312A1 (en) | External preparation for transdermal administration | |
| CN117462483A (zh) | 加巴喷丁在制备用于治疗宠物瘙痒的乳膏制剂中的用途 | |
| KR20230064809A (ko) | 마그놀린을 유효성분으로 포함하는 신경병성 통증 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241028 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241028 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241029 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250404 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250714 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20251114 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251118 |